Sean Nolan

Track

Insider profile

Currently holds positions in Neurogene Inc., InterMune Inc and AveXis Inc

Performance

Overall performance
1.1
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -1% 8.2% 15.1%
Success rate 3% 68% 82%
Transactions
3 33% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return -79%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Director Neurogene Inc. Feb. 1, 2015 -
Executive Vice President, Chief Business Officer InterMune Inc Feb. 14, 2013 -
President, Chief Executive Officer AveXis Inc May 15, 2018 -
President, Chief Executive Officer, Director AveXis Inc June 1, 2015 - May 15, 2018
Sean Nolan's trades of Taysha Gene Therapies Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-27 2026-01-26
S Sale
43,996 -17.7%
195.39
US$1,834,300 		43,996 -17.7% 195.39 US$1,834,300
2026-01-27 2026-01-23
S Sale
46,794 +34.4%
422.78
US$1,929,902 		46,794 +34.4% 422.78 US$1,929,902
2026-01-23 2026-01-23
PrS Proposed sale
84,282
229.81
US$4,314,730 		84,282 229.81 US$4,314,730
2023-08-16 2023-08-16
B Purchase
444,444 +40.7%
0.90
US$400,000 		444,444 +40.7% 0.90 US$400,000
2021-05-24 2021-05-20
B Purchase
1,170 +inf%
22.35
US$26,150 		1,170 +inf% 22.35 US$26,150